PMID- 25163670
OWN - NLM
STAT- MEDLINE
DCOM- 20150622
LR  - 20191113
IS  - 2212-4063 (Electronic)
IS  - 1871-529X (Linking)
VI  - 14
IP  - 3
DP  - 2014
TI  - Interaction between thienopyridines and proton pump inhibitors.
PG  - 240-5
AB  - Adenosin diphospat (ADP) plays a crucial role in thrombus formation. Therefore 
      its inhibition can control excess platelet generation to prevent cardiovascular 
      events in patients with acute coronary syndrome (ACS) or undergoing percutaneous 
      coronary intervention (PCI). One of ADP's target receptors, P2Y12 has a limited 
      tissue distribution and is therefore an attractive pharmacological target. 
      Thienopyridines are class of drugs that specifically and irreversibly inhibit the 
      P2Y12 receptor. Three generations exist and in most patients, they are 
      administered in combination with aspirin. Because of possible gastro-intestinal 
      toxicity, a proton pump inhibitor (PPI) is often concomitantly prescribed. 
      However, several studies suspect an interaction between thienopyridines (in 
      particular with clopidogrel) and PPIs which decreases the inhibition of platelet 
      formation and thus enhances the risk for cardiac events. In this review, a 
      concise overview of pharmacokinetic and pharmacodynamic properties of all 
      thienopyridines is given and a critical discussion of the presumed interaction 
      with PPIs is provided.
FAU - Yildiz, Banu Sahin
AU  - Yildiz BS
FAU - Yildiz, Mustafa
AU  - Yildiz M
FAU - Akin, Ibrahim
AU  - Akin I
AD  - Department of Cardiology, University of Mannheim, Theodor-Kutzer Ufer, 1-3, 68167 
      Mannheim, Germany. akinibra@med.uni-rostock.de.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Cardiovasc Hematol Disord Drug Targets
JT  - Cardiovascular & hematological disorders drug targets
JID - 101269160
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 0 (Thienopyridines)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
SB  - IM
MH  - Adenosine Diphosphate/metabolism
MH  - Drug Interactions
MH  - Humans
MH  - Proton Pump Inhibitors/*pharmacology
MH  - Purinergic P2Y Receptor Antagonists/adverse 
      effects/*pharmacokinetics/pharmacology
MH  - Thienopyridines/adverse effects/*pharmacokinetics/pharmacology
MH  - Thrombosis/prevention & control
EDAT- 2014/08/29 06:00
MHDA- 2015/06/24 06:00
CRDT- 2014/08/29 06:00
PHST- 2014/02/21 00:00 [received]
PHST- 2014/04/30 00:00 [revised]
PHST- 2014/04/30 00:00 [accepted]
PHST- 2014/08/29 06:00 [entrez]
PHST- 2014/08/29 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - CHDDT-EPUB-61885 [pii]
AID - 10.2174/1871529x14666140823121002 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Disord Drug Targets. 2014;14(3):240-5. doi: 
      10.2174/1871529x14666140823121002.